在非小细胞肺癌的新辅助疗法和手术后的辅助化疗
Ryo Miyata1, Masatsugu Hamaji2, Akiyoshi Nakakura3
1Department of Thoracic Surgery, Kagoshima University Hospital, Kagoshima, Japan.
Annals of thoracic surgery short reports
|January 10, 2025
概括
在局部晚期非小细胞肺癌 (NSCLC) 的新辅助疗法和手术后的辅助化疗没有改善生存结果. 这项研究发现,在接受术后化疗的患者中,无复发性存活率或整体存活率没有显著的益处.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 医学瘤学 医学瘤学
背景情况:
- 关于术后化疗在新辅助疗法和局部晚期非小细胞肺癌 (NSCLC) 手术后的疗效的数据有限.
- 了解辅助化疗对生存的影响对于优化这种患者群体的治疗至关重要.
研究的目的:
- 为了比较生存结果,包括总生存率 (OS) 和无复发生存率 (RFS),在接受辅助化疗的局部晚期NSCLC患者与未接受辅助化疗的患者之间,在新辅助疗法和手术后.
主要方法:
- 在2009-2016年期间接受治疗的156名可切除NSCLC (cT3 N0或N1-N2) 患者的回顾性图表审查.
- 倾向性得分匹配 (PSM) 被用于最小化选择偏差,当比较群体之间的生存.
- 使用Kaplan-Meier分析和Cox比例危险模型来评估OS和RFS.
主要成果:
- 在PSM之前,辅助化疗与显著较短的RFS (HR 1.79) 和较短的OS (HR 1.37) 趋势有关.
- 在PSM后,接受辅助化疗和不接受辅助化疗的患者之间没有观察到RFS (HR 1.33) 或OS (HR 1.25) 的显著差异.
- 整个队列的中位数RFS为66.3个月,没有达到OS.
结论:
- 随着局部晚期NSCLC的新辅助疗法和手术后的辅助化疗与改善的生存结果无关.
- 这些发现表明需要重新评估辅助化疗在这种特定的临床环境中的作用.
更多相关视频
13:37A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
Published on: March 12, 2014
29.9K
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.5K
相关概念视频
Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
